ArticleCureus2026
Isolated Cerebral Metastasis in Ovarian Cancer: A Report of a Rare Case.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases in ovarian cancer are uncommon, yet they signify aggressive disease and are associated with limited survival. This case highlights the diagnostic challenges and therapeutic dilemmas in managing central nervous system (CNS) involvement in ovarian cancer, given the lack of standardized protocols. This report adheres to the Surgical Case Report (SCARE) 2025 checklist. A 58-year-old woman with stage IIIB high-grade serous ovarian carcinoma in systemic remission developed a solitary frontal lobe metastasis 18 months after initial diagnosis. The diagnosis was suspected on MRI and confirmed by histopathological analysis after gross total resection of the tumor. While surgical intervention, as in this case, can provide symptomatic relief and pathological confirmation, the prognosis for patients with CNS metastases from ovarian cancer remains poor. This underscores the need for two key approaches in high-risk patients (e.g., those with residual postoperative tumor or unfavorable molecular markers): first, enhanced surveillance, implying more frequent imaging and a lower threshold for initiating adjuvant therapy, and second, the exploration of novel CNS-penetrating therapies. This case illustrates that even with aggressive local treatment for a solitary brain metastasis, outcomes are often unfavorable. It emphasizes the importance of a high index of suspicion for neurological symptoms in ovarian cancer patients and highlights the urgent need for more effective treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.